T1	intervention 98 122	PI3K inhibitor alpelisib
T2	intervention 128 139	fulvestrant
T3	eligibility 143 191	patients with HR-positive advanced breast cancer
T4	intervention-participants 959 962	284
T5	control 967 974	placebo
T6	control-participants 980 983	287
T7	outcome 1002 1015	grade 3/4 AEs
T8	outcome 1036 1049	hyperglycemia
T9	outcome 1051 1058	grade 3
T10	outcome 1067 1074	grade 4
T11	outcome 1083 1087	rash
T12	outcome 1089 1096	grade 3
T13	outcome 1109 1117	diarrhea
T14	outcome 1119 1126	grade 3
T15	outcome 1135 1176	Median time to onset of grade ≥3 toxicity
T16	outcome 1449 1458	incidence
T17	outcome 1460 1469	any grade
T18	intervention-value 1471 1476	26.7%
T19	control-value 1484 1489	64.1%
T20	outcome 1495 1511	severity of rash
T21	intervention-value 1522 1527	11.6%
T22	control-value 1535 1540	22.7%
T23	outcome 1577 1613	Discontinuations due to grade ≥3 AEs
T24	intervention-value 1675 1679	7.9%
T25	control-value 1687 1692	18.1%
T26	outcome 1790 1822	Median progression-free survival
